Pharmaceuticals News and Research

RSS

Lotus Pharmaceuticals first-quarter net income up 38%

Lotus Pharmaceuticals, Inc., a growing developer, manufacturer and seller of medicine and drugs in the People's Republic of China today reported its financial results for the first quarter ended March 31, 2010.

15 May 2010

FDA assigns Cadence Pharmaceuticals' OFIRMEV NDA new PDUFA action date

Cadence Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has classified the OFIRMEV™ (acetaminophen) injection New Drug Application (NDA) resubmission as a complete Class 2 response to the FDA's February 10, 2010 action letter and assigned a new Prescription Drug User Fee Act (PDUFA) action date of November 4, 2010.

15 May 2010

FDA grants tentative approval for Teva's Cinacalcet HCl Tablets ANDA

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration (FDA) has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) for Cinacalcet HCl Tablets 30, 60 & 90 mg.

15 May 2010

Nymox attributes increase in first-quarter net losses to higher clinical trial expenditures

Nymox Pharmaceutical Corporation announced today its financial results for the first quarter of 2010. Nymox reported a net loss of $1,269,550, or $0.04 per share for the quarter ending March 31, 2010, compared to $1,004,259, or $0.03 per share for same period in 2009. Net losses include stock compensation charges of $195,220 in 2010 and $309,650 in 2009.

14 May 2010

BioSante Pharmaceuticals first-quarter net loss increases to $10.5 million

BioSante Pharmaceuticals, Inc. today reported on its recent developments and financial results for the first quarter, and its cash balance as of March 31, 2010.

14 May 2010

Nutrastar International's first-quarter 2010 revenues up 2.7%

Nutrastar International Inc., a leading nutraceutical company which produces and distributes Chinese Golden Grass and organic and specialty food products in China, today announced its financial results for the first quarter 2010.

14 May 2010

Hana Biosciences reports $5.5 million net loss for first-quarter 2010

Hana Biosciences Inc.,, a biopharmaceutical company focused on strengthening the foundation of cancer care, today reported financial results for the first quarter ended March 31, 2010, and provided a corporate update.

14 May 2010

Caliper Life Sciences' CDAS unit awarded new funding commitment for EPA ToxCast screening program

Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery and life sciences research, today announced that its Caliper Discovery Alliances and Services (CDAS) unit has been awarded a new funding commitment for $2.9 million under its contract with the Environmental Protection Agency for the EPA's ToxCast screening program.

14 May 2010

FDA grants tentative approval for Impax Laboratories' generic Opana ER

Impax Laboratories, Inc. today confirmed that the U.S. Food and Drug Administration (FDA) has granted tentative approval of the Company's Abbreviated New Drug Application (ANDA) for generic version of Opana® ER (oxymorphone hydrochloride) 5, 7.5, 10, 15, 20, 30 and 40 mg tablets.

14 May 2010

Clondalkin Group plans to strengthen its position in the European pharmaceutical and healthcare sector

International packaging producer Clondalkin Group has revealed plans to further strengthen its position in the European pharmaceutical and healthcare sector.

14 May 2010

EPA continues to validate ToxCast screening tool by testing more than 100 drugs

The U.S. Environmental Protection Agency will continue validating its ToxCast screening tool by screening more than 100 drugs provided by Pfizer, GlaxoSmithKline, Sanofi-Aventis, and Merck. These drugs never entered the marketplace because they demonstrated different types and levels of toxicity when the pharmaceutical companies conducted the early stage clinical trials required by the Food and Drug Administration as part of the drug development process.

14 May 2010

Prometheus announces novel method for early detection of HACA during infliximab treatment

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced a new method for detecting antibody levels in individual patients treated with infliximab, a biologic therapy that has been used to treat more than a million patients across a number of autoimmune diseases, including rheumatoid arthritis, Crohn's disease and ulcerative colitis.

14 May 2010

India, Brazil launch trade dispute against EU, Netherlands over seizures of generic drugs

"India and Brazil launched a trade dispute against the European Union and the Netherlands on Wednesday, saying their seizures of generic drugs were hurting healthcare in poor countries and disrupting international trade," Reuters reports.

14 May 2010

Novel vaccines for deadly diseases to be presented at AAPS' NBC

Novel vaccines for diseases ranging from the flu to HIV highlight a week's worth of biotechnology research at the American Association of Pharmaceutical Scientists' National Biotechnology Conference. Scientists from academia, industry, and government will gather at the Hilton San Francisco Union Square Sunday, May 16 -Thursday, May 20 to share research and advances in biotherapeutics.

14 May 2010

Johns Hopkins Children's Center neonatologist joins NQF HIT advisory committee

Johns Hopkins Children's Center neonatologist Christoph Lehmann, M.D., has joined the nation's leading watchdog organization on health-care quality, the National Quality Forum (NQF), as a member of its newly formed Health Information Technology (HIT) advisory committee.

14 May 2010

BIO-key International first-quarter total revenue up 81%

BIO-key International, Inc., a leader in finger-based biometric identification solutions, today reported financial results for the first quarter ended March 31, 2010. For clarity and consistency, the data presented in this release includes only the results of the Company's fingerprint-based Biometrics Division for such period. The Company completed the sale of its Law Enforcement Division on December 8, 2009.

14 May 2010

caprotec bioanalytics closes EUR 4 million Series B Financing Round

caprotec bioanalytics GmbH today announced the closing of a EUR 4 million ($5.1M) Series B Financing Round with existing investors Creathor Venture, IBB Beteiligungsgesellschaft, ERP Startfonds, and well-known private investors. The proceeds will enable further development and marketing of the Company's proprietary CCMS (Capture Compound Mass Spectrometry) platform technology for analyzing complex protein mixtures.

14 May 2010

Phase IIb trail results of epratuzumab in lupus patients to be presented at EULAR 2010

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that clinical trial results on epratuzumab, the anti-CD22 humanized monoclonal antibody licensed to UCB SA, Brussels, for autoimmune disease indications, from the Phase IIb study in patients with lupus, will be presented in four posters sessions and one published abstract.

14 May 2010

Transdel Pharmaceuticals reports lower net loss of $0.9 million for first-quarter 2010

Transdel Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing topically administered products using its proprietary transdermal delivery platform, today announced financial results for the quarter ended March 31, 2010. The Company also highlighted recent achievements.

14 May 2010

Response Genetics first-quarter total revenue up 140%

Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, today announced its consolidated financial results for the three months ended March 31, 2010.

14 May 2010

Pharmaceuticals News and Research

Lotus Pharmaceuticals first-quarter net income up 38%

FDA assigns Cadence Pharmaceuticals' OFIRMEV NDA new PDUFA action date

FDA grants tentative approval for Teva's Cinacalcet HCl Tablets ANDA

Nymox attributes increase in first-quarter net losses to higher clinical trial expenditures

BioSante Pharmaceuticals first-quarter net loss increases to $10.5 million

Nutrastar International's first-quarter 2010 revenues up 2.7%

Hana Biosciences reports $5.5 million net loss for first-quarter 2010

Caliper Life Sciences' CDAS unit awarded new funding commitment for EPA ToxCast screening program

FDA grants tentative approval for Impax Laboratories' generic Opana ER

Clondalkin Group plans to strengthen its position in the European pharmaceutical and healthcare sector

EPA continues to validate ToxCast screening tool by testing more than 100 drugs

Prometheus announces novel method for early detection of HACA during infliximab treatment

India, Brazil launch trade dispute against EU, Netherlands over seizures of generic drugs

Novel vaccines for deadly diseases to be presented at AAPS' NBC

Johns Hopkins Children's Center neonatologist joins NQF HIT advisory committee

BIO-key International first-quarter total revenue up 81%

caprotec bioanalytics closes EUR 4 million Series B Financing Round

Phase IIb trail results of epratuzumab in lupus patients to be presented at EULAR 2010

Transdel Pharmaceuticals reports lower net loss of $0.9 million for first-quarter 2010

Response Genetics first-quarter total revenue up 140%

Drug Discovery - Second Edition eBook

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News